Iryna A. Kryachok
33/43 Lomonosova Str
03022, Ukraine
03022, Ukraine
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Metabolic heterogeneity-based radiomic model predicts treatment outcomes of primary mediastinal B-cell lymphoma patients in the IELSG37 study.
Journal: British journal of haematology
Published: February 19, 2026
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 01, 2025
The signs of negative selection in IGHV framework regions are associated with worse overall survival of chronic lymphocytic leukemia patients.
Journal: Leukemia research
Published: June 24, 2021
Clinical relevance of TP53 polymorphic genetic variations in chronic lymphocytic leukemia.
Journal: Leukemia research
Published: February 07, 2017
Health-related quality of life and patient-reported outcomes of ofatumumab plus fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide in the COMPLEMENT 2 trial of patients with relapsed CLL.
Journal: Leukemia & lymphoma
Published: November 11, 2016
Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial.
Journal: Leukemia & lymphoma
Published: October 13, 2016
Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia.
Journal: Leukemia & lymphoma
Published: January 20, 2016
IMMUNOHISTOCHEMICAL FACTORS OF SMALL-CELL LYMPHOMAS AND CHOICE OF TREATMENT WTTH LEVEL INCLUSION
Journal: Likars'ka sprava
Published: December 08, 2015
CD38 gene polymorphism and risk of chronic lymphocytic leukemia.
Journal: Leukemia research
Published: February 28, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026